Smith & Nephew (LON:SN) Price Target Cut to GBX 1,250 by Analysts at Berenberg Bank

Smith & Nephew (LON:SN) had its price target decreased by research analysts at Berenberg Bank from GBX 1,300 to GBX 1,250 in a report issued on Friday,London Stock Exchange reports. The brokerage presently has a “hold” rating on the stock. Berenberg Bank’s target price points to a potential upside of 13.07% from the stock’s current price.

A number of other research firms also recently weighed in on SN. Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. Shore Capital Group restated a “buy” rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,400 target price on shares of Smith & Nephew in a research report on Thursday, July 30th. Jefferies Financial Group reissued a “buy” rating and set a GBX 1,500 price target on shares of Smith & Nephew in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada cut their price objective on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of GBX 1,310.

Smith & Nephew Stock Performance

SN opened at GBX 1,105.50 on Friday. The business has a 50-day moving average of GBX 1,135.64 and a 200 day moving average of GBX 1,189.09. The firm has a market capitalization of £12.12 billion, a PE ratio of 39.80, a PEG ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.